The US plans to shoot COVID-19 at six months instead of eight – WSJ

August 25 (Reuters) – U.S. health regulators could approve a third shot of COVID-19 for adults starting at least six months after full vaccination, instead of the eight-month gap previously announced, it reported Wednesday the Wall Street Journal.

Approval of reinforcements for three U.S.-administered COVID-19 features: those manufactured by Pfizer Inc. (PFE.N) and its partner BioNTech SE (22UAy.DE), Modern Inc. (MRNA.O) and Johnson & Johnson JNJ.N) – is expected in mid-September, according to the report, which cites a person familiar with the plans.

Pfizer and BioNTech have already begun the application process for approval of their booster shot in people over the age of 16, saying it stimulates more than a triple increase in antibodies against coronavirus. Read more

Earlier this week, U.S. regulators granted full approval to the two-dose Pfizer vaccine. Modern said Wednesday it has completed the real-time review needed for full approval of its coup on people over 18. Read more

White House spokeswoman Jen Psaki said in her daily report that this development would be under the jurisdiction of the Centers for Disease Control, Prevention and Control (CDC).

The CDC said the government’s plan to administer a booster shot depends on the pending action of the Food and Drug Administration and the recommendation of the Advisory Committee on Immunization Practices.

The FDA, however, reiterated its joint statement last week that the government was preparing to launch the third shot from mid-September on Americans who had the initial course of dose vaccines made by Modern and Pfizer for over eight months. does.

Deployment would begin if the FDA and CDC decide they need boosters, U.S. officials had said. Read more

Reports from Manojna Maddipatla to Bengaluru; Edited by Arun Koyyur

Our standards: the principles of trust of Thomson Reuters.